share_log

RMG-KB BIOACCESS FUND LAUNCHES with Worldwide Focus on Innovative Life Sciences Ventures

RMG-KB BIOACCESS FUND LAUNCHES with Worldwide Focus on Innovative Life Sciences Ventures

RMG-KB BIOACCESS基金推出,全球關注創新生命科學風險投資
PR Newswire ·  2021/09/07 19:10

NEW YORK, Sept. 7, 2021 /PRNewswire/ -- RM GLOBAL PARTNERS, LLC (RMG) today announced that it has launched the RMG-KB BioAccess Fund, L.P. (the "Global BioAccess Fund") with KB Investment Co. Ltd. (KBI). The fund, which completed its first closing of $60 million, will focus exclusively on innovative venture investments in biopharmaceuticals and medical technology worldwide.

紐約9月2021年7月/美通社/--RM Global Partners,LLC(RMG)今天宣佈,它已推出RMG-KB BioAccess Fund,L.P.(“全球生物接入基金”)與KB投資有限公司(KBI)合作。該基金完成了6000萬美元的首次募集,將專門專注於全球生物製藥和醫療技術領域的創新風險投資。

This latest fund represents a significant expansion of the principal investment business of RMG, building on the team's 25-plus year history in life sciences banking, investment and innovation.  KBI brings unique expertise and capabilities with more than 30 years of investment history to the fund. The RMG managing directors leading the fund will be Ted Moon, Bruce Roberts, and Lisa Wisniewski, Ph.D., joined on the investment committee by Lambert Kuk and Min Shin, Pharm.D. from KBI. In addition, the fund management team is being expanded and now includes Sonia Gulati, Ph.D.as a principal.

這隻最新的基金代表着RMG在生命科學銀行、投資和創新領域25年多歷史的基礎上,其主要投資業務的顯著擴張。KBI為該基金帶來了獨特的專業知識和能力,擁有30多年的投資歷史。領導該基金的RMG董事總經理將是泰德·穆恩(Ted Moon)。布魯斯·羅伯茨,和麗莎·威斯涅夫斯基(Lisa Wisniewski)博士通過以下方式加入了投資委員會蘭伯特·庫克(Lambert Kuk)和閔欣,KBI的藥學博士。此外,基金管理團隊正在擴大,目前包括索尼婭·古拉蒂,以校長身份獲得博士學位。

"We are deeply grateful to our partners for their commitment to the Global BioAccess Fund and their confidence in our ability to access exciting opportunities through the global network we have developed over many years," said Ted Moon. "As life sciences enters into a new era of historic innovation, we are honored to be supporting talented entrepreneurs and science," commented Bruce Roberts.

泰德·穆恩説:“我們非常感謝我們的合作伙伴對全球生物接入基金的承諾,以及他們對我們有能力通過我們多年來發展起來的全球網絡獲得令人興奮的機會的信心。”布魯斯·羅伯茨評論説:“隨着生命科學進入歷史性創新的新時代,我們很榮幸能為有才華的企業家和科學提供支持。”

The management of the Global BioAccess Fund anticipates that the fund will generate multiple opportunities to build innovative biotech companies that can bring medical advances. "It is our goal that the Fund will be the center of a true ecosystem for growing and supporting global leaders in biotechnology and medical technology," said Jong Pil Kim, CEO of KBI.

全球生物獲取基金(Global BioAccess Fund)的管理層預計,該基金將創造多種機會,以建立能夠帶來醫學進步的創新型生物技術公司。KBI首席執行官Jong Pil Kim表示:“我們的目標是,該基金將成為一個真正生態系統的中心,以培育和支持生物技術和醫療技術領域的全球領先者。”

About RM GLOBAL PARTNERS

關於RM全球合作伙伴

RM Global Partners (RMG) is a global investment banking and strategic advisory firm specialized in life sciences, including biopharma, biotech, medical devices, and digital health, The team possesses broad expertise in M&A, financing, operations and strategy, having backed and supported multiple leading life sciences companies over several decades. Since the founding of the business in the 1990's, RMG has fostered a deep network of industry relationships in the Americas, Europe, Israel, and Asia: Korea, Japan, and China. For more information please visit http://www.rmglobal.com.

RM Global Partners(RMG)是一家專門從事生命科學(包括生物製藥、生物技術、醫療設備和數字健康)的全球投資銀行和戰略諮詢公司,該團隊在併購、融資、運營和戰略方面擁有廣泛的專業知識,幾十年來曾支持和支持過多家領先的生命科學公司。自20世紀90年代成立以來,RMG已在美洲、歐洲、以色列和亞洲:韓國,日本和中國。欲瞭解更多信息,請訪問http://www.rmglobal.com.。

About KB INVESTMENT, CO., LTD.

關於KB投資有限公司

KB Investment Co., Ltd. (KBI) is a recognized leading Korean venture capital firm that is 100% subsidiary of KB Financial Group (KRX: 105560,NYSE: KB). KBI has 30+ years of investments and successful track records with 150+ portfolio company IPOs. KBI primarily invests in the companies globally that can translate cutting-edge technologies into transformative business. For more information, please visit http://www.kbic.co.kr.

KB投資有限公司是一家公認的領先的韓國風險投資公司,是KB金融集團(韓國證券交易所代碼:105560,紐約證券交易所代碼:KB)的100%子公司。KBI擁有30多年的投資經驗和150多家投資組合公司首次公開募股(IPO)的成功記錄。KBI主要投資於全球能夠將尖端技術轉化為變革性業務的公司。欲瞭解更多信息,請訪問網址:http://www.kbic.co.kr.。

CONTACT: Ted Moon, [email protected]

聯繫人:泰德·穆恩[受電子郵件保護]

SOURCE RM Global Partners LLC

來源RM全球合作伙伴有限責任公司

Related Links

相關鏈接

www.rmglobal.com

Www.rmglobal.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論